Debinski Research Interests

The main goal of my laboratory is to advance research in the areas of unmet needs in medicine; a majority of primary brain tumors represents such needs.

Our focus is on the identification of molecular markers/targets that are specific to brain tumors.

We have uncovered several markers/targets that are present in most patients with glioblastoma multiforme (GBM), a brain tumor of dismal prognosis, but absent in normal organs.

One of these markers/targets is a restricted receptor for interleukin 13 (IL13) which utility for therapeutic interventions has already been demonstrated. For example, the first generation of our IL13-based cytotoxins, recombinant proteins that kill cancer cells via the restricted IL13 receptor, has accomplished Phase III clinical efficacy trials.

We have also uncovered a new ubiquitous oncogene-inducible factor that promotes blood vessels growth in GBM and a subset of specific transcription factors the activity of which may play a paramount role in GBM progression.

Most recently, our work has unraveled the presence and important function in GBM of one of the protein tyrosine kinase receptors, EphA2. New diagnostic/imaging/therapeutic strategies are being developed based on all these findings in order to improve the management of patients with brain tumors.

Last Updated: 07-24-2014
USNWR 2013-2014Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.